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Zusammenfassung
Hintergrund: Metaanalysen zeigten die Überlegenheit 
von taxanhaltigen Chemotherapien gegenüber rein 
 anthrazyklinbasierten Therapieregimen bei Hochrisiko-
Mammakarzinompatientinnen. Patienten und Methode: 
Die ADEBAR-Studie, als multizentrische Phase-III-Studie, 
randomisierte nodalpositive Mammakarzinompatien-
tinnen entweder in den sequentiellen Anthrazyklin- 
Taxan-Arm oder in den FEC120-Arm. Die Patientinnen 
erhielten 4× Epirubicin (90 mg/m2) und Cyclophosphamid 
(600 mg/m2) q3w, gefolgt von 4× Docetaxel (100 mg/m2) 
q3w (EC-Doc-Arm) oder 6× Epirubicin (60 mg/m2) und 
5-Fluoroura cil (500 mg/m2) an den Tagen 1 und 8 und 
 Cyclophosphamid (75 mg/m2) an den Tagen 1–14, q4w 
(FEC-Arm). Wir verglichen beide Arme bezüglich der 
 Toxizitäten.  Ergebnisse: Hämatologische Toxizität fand 
sich signifikant häufiger im FEC-Arm. Febrile Neutro-
penie trat bei 11,3% der Patientinnen im FEC-Arm 
auf sowie bei 8,4% der Patientinnen im EC-Doc-Arm 
(p = 0,027). Schwere nicht-hämatologische Neben-
wirkungen Grad 3/4 traten in beiden Armen selten auf. 
Aufgrund von Toxizitäten musste die Therapie bei 3,7% 
der Patientinnen im EC-Doc-Arm sowie bei 8,0% der Pati-
entinnen im FEC-Arm abgebrochen werden (p = 0,0009). 
Schlussfolgerung: Das sequentielle Anthrazyklin-Taxan-
Regime ist eine gut verträgliche Alternative zu FEC120. 
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Summary
Background: Data from meta-analyses have shown 
 taxane-containing therapies to be superior to anthra-
cycline-based treatments for high-risk breast cancer. 
 Patients and Methods: The ADEBAR trial was a multi-
center phase III trial in which patients with lymph node-
positive breast cancer were prospectively randomized 
for either sequential anthracycline-taxane or FEC120 
therapy. Patients received 4× epirubicin (90 mg/m2) and 
cyclophosphamide (600 mg/m2) every 3 weeks (q3w), fol-
lowed by 4× docetaxel (100 mg/m2) q3w (EC-Doc arm), or 
6× epirubicin (60 mg/m2) and 5-fluorouracil (500 mg/m2) 
on days 1 and 8 and cyclophosphamide (75 mg/m2) on 
days 1–14, q4w (FEC arm). We compared both arms with 
respect to toxicity and feasibility. Results: Hematological 
toxicity was found significantly more often in the FEC 
arm. Febrile neutropenia was seen in 11.3% of patients 
in the FEC arm and in 8.4% of patients in the EC-Doc arm 
(p = 0.027). Non-hematological side effects of grade 3/4 
were rarely seen in either arm. Therapy was terminated 
due to toxicity in 3.7% of the patients in the EC-Doc arm 
and in 8.0% of the patients in the FEC arm (p = 0.0009). 
Conclusion: The sequential anthracycline-taxane regi-
men is a well-tolerated and feasible alternative to FEC120 
therapy.
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Introduction
Adjuvant chemotherapy reduces the risk of cancer recurrence 
for patients with high-risk breast cancer [1]. However, the side 
effects of chemotherapy may cause problems that can even be 
life threatening. Therefore, it is of great importance to iden-
tify effective and well-tolerated chemotherapy regimens. In 
an effort to prolong disease-free and overall survival, doxo-
rucibin- or epirubicin-based regimens have replaced CMF 
(cyclophosphamide, methotrexate, fluorouracil) as the stand-
ard chemotherapy used in the adjuvant situations [2–5].
The 2 widely-used FEC (fluorouracil, epirubicin, cyclo-
phosphamide) regimens are the dose-dense FEC120 (Levine) 
(5-fluorouracil 500 mg/m2/intravenously (i.v.) days 1+8 every 
4 weeks (q4w), epirubicin 60 mg/m2/i.v. days 1+8 q4w and 
 cyclophosphamide 75 mg/m2/orally (p.o.) days 1–14 q4w) and 
the FEC100 (Boneterre) (5-fluorouracil 500 mg/m2/i.v. day 1 
q3w, epirubicin 100 mg/m2/i.v. day 1 q3w and cyclophospha-
mide 500 mg/m2/i.v. day 1 q3w) [2, 6]. Commonly observed 
side effects of FEC chemotherapy are myelosuppression, 
 febrile neutropenia, mucositis, nausea, vomiting and alopecia; 
each of those can cause great damage to the patients. FEC120 
chemotherapy that delivers a cumulative dose of 720 mg epi-
rubicin is thought to be more toxic than FEC100. Although 
studies comparing FEC100 and FEC120 are not available, 
 cardiotoxicity can be assumed to be a major problem of the 
higher anthracycline dose.
Taxanes have been added to chemotherapy regimens to 
improve the efficiency of breast cancer treatment. Initially, in 
the metastatic setting, they were superior to anthracyclines 
[7–9]. In the adjuvant situation, meta-analytic data showed a 
significant increase in disease-free and overall survival rates 
for patients following taxane therapy, in particular for pa-
tients with node-positive breast cancers [10–15]. On the other 
hand, treatment with the taxane compound docetaxel had 
shown severe side effects for patients, including neutropenia 
(76.4%), anemia (8.9%), neurological symptoms (4%), 
 stomatitis (5.3%), and dermal affections (5.9%).
In the present study, we investigated the feasibility of 
 epirubicin-based chemotherapy with or without a taxane by 
evaluating chemotherapy-induced toxicity in data from the 
ADEBAR trial.
Patients and Methods
The ADEBAR trial was a multicenter phase III trial for patients with 
high-risk breast cancer (≥ 4 involved lymph nodes). The trial primarily 
served to compare recurrence-free survival rates, and further aims were 
to compare overall survival, quality of life, and toxicity. 
Chemotherapy
Patients were prospectively randomized into 2 groups. For patients in 
Arm A (EC-Doc), 4 cycles of epirubicin at 90 mg/m2 and cyclophos-
phamide at 600 mg/m2 (EC) every 3 weeks (q3w) were followed by 4 cycles 
of docetaxel at 100 mg/m2 (Doc) q3w. For patients in Arm B (FEC120), 
6 cycles of epirubicin at 60 mg/m2 and 5-fluorouracil at 500 mg/m2 i.v. 
were given on days 1+8 with cyclophosphamide at 75 mg/m2 p.o. on 
days 1–14, q4w. 
Co-Medication and Supportive Care
Patients received co-medication with dexamethasone, mesna (sodium 
2-sulfanylethanesulfonate) and 5-HT3 antagonists. According to the 
study design, granulocyte colony-stimulating factor (G-CSF), erythro-
poietin and antibiotics were given when required. G-CSF was applied 
as a secondary prophylaxis in the following cases: febrile neutropenia; 
neutropenia (absolute neutrophil count (ANC) < 0.5 × 109/l) lasting more 
than 5 days; severe neutropenia (ANC < 0.1 × 109/l); and if an extension 
of the therapy interval was necessary due to insufficient levels of leuko-
cytes (< 3.0 × 109/l) or neutrophils (ANC < 1.5 × 109/l). Erythropoietin 
(300 mg/q2w or 150 mg/q1w) was recommended for chemotherapy-associ-
ated anemia (≤ 11 g/dl), or if hemoglobin levels decreased more than 
3 g/dl in 3 months. Prophylactic oral antibiotics were recommended if the 
levels of neutrophil granulocytes were < 0.5 × 109/l, regardless of G-CSF 
application. For febrile neutropenia, hospitalization and i.v. antibiotic 
therapies were recommended in the study protocol. 
Delay and Dose Reduction
Chemotherapy was delayed for a maximum of 2 weeks in cases of hema-
tological or non-hematological toxicity. A dose reduction by 1 level was 
performed successively for cases of severe hematological toxicity where 
secondary prophylactic application of G-CSF was unsuccessful. Non- 
hematological toxicities of grade 3 or 4 led to either a dose reduction or 
termination of the therapy. Minor cardiac symptoms, including isolated 
asymptomatic ventricular extrasystoles, were monitored, and patients 
were allowed to continue treatment. However, patients were removed 
from the study when arrhythmias required treatment or there was a 
 significant reduction in left ventricular ejection fraction (LVEF) (Study 
protocol of the ADEBAR-Trial, Version 3.0, 07/2003, 1). 
Data Collection
Data were collected using online clinical response forms. Data quality 
was controlled by a clinical research organization (CRO), which visited 
and monitored the study centers. Therapy-associated toxicity was evalu-
ated using the Common Toxicity Criteria of the NCI (National Cancer 
Institute), once before each chemotherapy cycle, and once 28 days after 
the end of chemotherapy. Electrocardiography (ECG) was performed 
 before each chemotherapy cycle and once 28 days after the end of chemo-
therapy, and echocardiography just before chemotherapy and 6 month 
after the last cycle or when cardiac symptoms occurred.
Statistical Analysis
Therapy-associated toxicities were compared using the χ2 test; Fisher’s 
exact test was used for cases of cell frequencies that were less than 5. 
A value of p < 0.05 was considered significant in 2-sided tests. No adjust-
ments of the error probability for multiplicity were performed. All analy-
ses were performed using Statistical Analysis Software Version 9.2 (SAS 
Institute Inc., Cary, NC, USA).
Results
From 2001 to 2005, 1,496 patients were included into the 
ADEBAR trial. Of these, 749 were randomly placed in the 
EC-Doc group, and 747 were placed in the FEC group. 
 Patient and tumor characteristics are shown in table 1. Com-
plete data sets for the evaluation of toxicity were available for 
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1,306 patients, including 661 in the EC-Doc group and 645 in 
the FEC group. The absence of any toxicity was rare and was 
found in only 0.8% of patients in the EC-Doc group and in 
0.9% in the FEC group. Toxicity grades of 1 and 2 were 
equally distributed in the EC-Doc group (13.5%) and the 
FEC group (12.9%). Similarly, toxicity grades of 3 and 4 were 
found in 85.8% of patients in the EC-Doc group and in 86.2% 
of patients in the FEC group. Severe adverse events (SAEs) 
were found in 21.3% of patients in the EC-Doc group and in 
28.4% of patients in the FEC group (p = 0.003). 
Hematological Toxicity
Hematological toxicity of grade 3 or 4 (table 2) was found 
more often in the FEC group. Leukopenia and neutropenia 
were the most frequent side effects in both groups. There was 
a highly significant difference (p = 0.001) in the rates of grade 
3/4 leukopenia between the groups (72% EC-Doc and 80% 
FEC). Febrile neutropenia, however, occurred significantly 
more frequently during FEC than during EC-Doc treatment 
(11.3% vs. 8.4%; p = 0.027). The application of G-CSF was 
only necessary in 39.2% of the EC-Doc patients, whereas 
G-CSF was given to 61.4% of the FEC patients (p < 0.001). 
More infections occurred in the FEC group (15.5%) than in 
the EC-Doc group (9.4%) (p = 0.001). Therefore, i.v. anti-
biotic therapy was necessary more often in the FEC group 
than in the EC-Doc group (19.7% vs. 10.4%; p < 0.001). 
 Anemia and thrombocytopenia were rarely found in the EC-
Doc group, but these conditions were more frequent in the 
FEC group (anemia 2.8% vs. 15.5%, thrombocytopenia 2% 
vs. 23.9%; p < 0.001). Thus, erythropoietin was given to only 
8.7% of patients in the EC-Doc group compared to 20% of 
patients in the FEC group (p < 0.001). 
Hematological Toxicity during the Course  
of EC-Doc Therapy
Significantly less leukopenia of grades 3 and 4 was found dur-
ing the application of EC (55.8%) than during the subsequent 
application of docetaxel (76.9%) (p < 0.001). The rates of 
neutropenia were similar, as 62.5% of patients receiving EC 
and 57.9% of those receiving docetaxel therapy (p = 0.291) 
developed this condition. Although G-CSF was given more 
often during docetaxel than EC therapy (26.2% vs. 11.3%; 
p < 0.0001), the higher incidence of leukopenia during doce-
taxel therapy could not be avoided. Anemia rarely occurred 
during the application of docetaxel (1.5%), but was found in 
7.5% of patients during the application of EC (p < 0.001). 
Table 1. Patient and tumor characteristics in the study population
EC-Doc FEC All 
Age (years)
Median/min.–max. 54/27–71 55/25–71 55/25–71
n (%) n (%) n (%)
Menopausal status
Premenopausal 250 (37.0) 245 (37.4)  495 (37.2)
Postmenopausal 417 (61.7) 406 (62.0)  823 (61.8)
ECOG performance status
0 524 (77.5) 486 (74.2) 1010 (75.9)
1 124 (18.3) 131 (20.0)  255 (19.2)
Histological subtype
Ductal 479 (70.9) 450 (68.7)  929 (69.8)
Lobular 141 (20.9) 138 (21.1)  279 (21.0)
Other  51 (7.5) 60 (9.2)  111 (8.3)
Tumor size
T1 193 (25.8) 198 (26.5)  391 (26.1)
T2 393 (52.5) 358 (47.9)  751 (50.2)
T3  84 (11.2)  81 (10.8)  165 (11.0)
T4  57 (7.6)  72 (9.6)  129 (8.6)
Number of positive axillary lymph nodes
≥ 4 458 (61.1) 457 (61.2)  915 (61.2)
≥ 10 291 (38.9) 290 (39.1)  581 (38.8)
Histological grade
Grade 1+2 342 (50.6) 332 (50.7)  674 (50.6)
Grade 3 292 (43.2) 262 (40.0)  554 (41.6)
Hormone receptor status
Positive 503 (74.4) 494 (75.4) 1117 (74.7)
Negative 173 (25.6) 161 (24.6)  379 (25.3)
EC-Doc = 4× epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks (q3w), followed by 4× docetaxel (100 mg/m2) q3w therapy, 
FEC = 6× epirubicin (60 mg/m2) and 5-fluorouracil (500 mg/m2) on days 1 and 8 and cyclophosphamide (75 mg/m2) on days 1–14, q4w therapy, 
ECOG = Eastern Cooperative Oncology Group.
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The most frequently observed event in the EC-Doc group as 
pain (14.2%), especially arthralgia and myalgia (12.3%), 
which was seldom found in the FEC group (pain 3.6% 
and arthralgia/myalgia 1.4%; p < 0.001). There was a signifi-
cant difference in the frequency of patients who experienced 
severe vomiting between the EC-Doc (6.2%) and FEC (2.8%) 
groups (p = 0.003). Neurological symptoms of grade 3 or 
4 and skin affections occurred almost exclusively in the 
EC-Doc group (vs. FEC group) with 3.9% (0.3%) and 4.2% 
of patients (0.8%) (p < 0.001), respectively, having these 
 conditions. This effect was mostly due to the administration 
of  docetaxel in the EC-Doc group. Cardiac impairments 
 according to NCI criteria of grade 3 or 4 were rare, and their 
frequencies were not statistically different between groups 
(1.1% FEC vs. 0.3% EC-Doc) (p = 0.1). Severe edema was 
also seldom found, but occurred significantly more often in 
the EC-Doc group (2.6%) than in the FEC group (0.3%) 
(p < 0.001).
Dose Reduction, Treatment Delay, Treatment Termination 
and Death during the Trial
The full set of chemotherapy cycles outlined in the study pro-
tocol was administered to 80.3% of patients in the EC-Doc 
group and to 77.1% of patients in the FEC group (p = 0.16). 
Erythropoietin was administered more often during docetaxel 
(4.3%) than during EC (1.9%) therapy (p < 0.0001), although 
the rate of anemia was higher during EC therapy. 
Hematological Toxicity during the Course of FEC
During the 6 cycles of therapy for the FEC group, anemia 
grade 3/4 was observed in approximately 15% of the patients. 
There was greater use of erythropoietin in this treatment 
group; it was given to 6.3% of patients in the first 3 cycles and 
to 12.7% during the second 3 cycles (p < 0.0001). We found a 
similar phenomenon for thrombopenia; there were more 
grade 3 and 4 events in the second half of FEC therapy 
(25.3%) than in the first half of therapy (18%) (p = 0.079). 
During the application of FEC, the percentages of patients 
with leukopenia and neutropenia remained steady, although 
there were small decreases from the initial levels of 81.6% to 
79.2% (p = 0.49) in cycles 1–3 and from 68.4% to 58.0% 
(p = 0.013) in cycles 4–6. This correlated with an increased 
 administration of G-CSF in the second half of FEC (47.4% vs. 
32.1% in the first half; p < 0.0001).
Non-Hematological Toxicity
In contrast to hematological toxicities, severe non-hematolog-
ical toxicities of grades 3 and 4 (table 3) were rarely found. 
Table 2. Hematological toxicity – relative frequency of adverse events
EC-Doc, % FEC, % p value
Anemia grade 3/4  2.8 15.5  < 0.001
Application of erythropoietin (per cycle)  8.7 20  < 0.001
Neutropenia grade 3/4 59.1 61.1 0.5
Leukopenia grade 3/4 72.0 79.8 0.001
Application of G-CSF (per cycles) 39.2 61.4 < 0.001
Infections  9.4 15.5 0.001
Intravenous antibiotics (per cycle) 10.4 19.7 < 0.001
Febrile neutropenia  8.4 11.3 0.027
Thrombocytopenia grade 3/4  2.0 23.9 < 0.001
G-CSF = Granulocyte colony-stimulating factor.
Table 3. Non-hematological toxicity of grades 3 and 4 – relative frequency of adverse events
EC-Doc, % FEC, % p value
Elevation of liver enzymes grade 3/4  
Bilirubin/transaminases  1.2/1.4 0.3/1.9 0.11/0.52
Gastrointestinal symptoms grade 3/4
Nausea/vomiting  5.1/6.2 4.7/2.8 0.7/0.003
Diarrhea  2.7 2.3 0.7
Mucositis  8.9 8.7 0.9
Cardiac symptoms grade 3/4  0.3 1.1 0.10
Edema  2.6 0.3  < 0.001
Neurological symptoms grade 3/4  3.9 0.3  < 0.001
Dermatologic symptoms grade 3/4  4.2 0.8  < 0.001
Allergy grade 3/4  0.5 0 0.25
Fever  1.1 0.8 0.8
Pain in general grade 3/4 14.2 3.6 < 0.001
Arthralgia, myalgia grade 3/4 12.3 1.4 0.001
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cycline-based regimen. No existing studies have directly com-
pared FEC120 therapy with FEC100, but it is likely that the 
FEC120 group would have higher levels of toxicity because of 
the greater cumulative amount of chemotherapeutic agents. 
Hematological toxicity and its complications are the great-
est challenge in adjuvant chemotherapy for breast cancer. Our 
data analysis has shown that hematological toxicity, especially 
neutropenia, is the main side effect of anthracycline and 
 taxane-based chemotherapy, as also observed in the NSABP-
B-28 and the PACS-01 trials [10, 12, 21]. We found myelotox-
icity to be the most common toxicity of grade 3/4 for both 
groups. The high rate of neutropenia (approximately 60%) 
was managed well with secondary G-CSF treatment. Primary 
application of G-CSF or pegfilgastrim in other docetaxel 
 regimens could have influenced the comparability of the tox-
icity data [22]. According to the PACS 01 trial, anemia and 
thrombocytopenia were not the main complications resulting 
from taxane-based therapy [12, 21], while these complications 
 occurred more often during FEC therapy. Overall, hemato-
logical toxicity was seen to be the most frequent side effect 
in FEC120 therapy. Febrile neutropenia occurred in 11.3% 
(FEC) and 8.4% (EC-Doc) of patients. Similar rates of febrile 
neutropenia were seen in the sequential anthracycline-taxane 
arm of the BCIRG 005 trial (8.3%) and in the PACS01 trial 
(11%) [12]. Overall, the rates of hematological toxicities in 
the ADEBAR trial are equivalent to those seen in other 
trials. 
Severe non-hematological side effects were mainly associ-
ated with taxane therapy. Arthralgia and myalgia (12.3%) 
were major complications in the EC-Doc group, but were 
 seldom found in the FEC group (< 4%). Severe docetaxel- 
associated neurotoxicity and skin affection were each found in 
4% of patients in the taxane group and in < 1% of patients in 
the anthracycline group. Patients with neurological toxicities 
of an NCI grade > 2 were removed from the trial. The 
NSABP-B28 trial found a similar rate of arthralgia and/or 
 myalgia in patients from the taxane arm (12%), but a higher 
rate of neurotoxicity in patients (15%) who received pacli-
taxel [10]. Long-term data regarding neurotoxicity from the 
ADEBAR trial are not yet available, and need to be the sub-
ject of further evaluation.
Anthracycline-associated cardiac impairments seldom 
 occurred during the observation period. Cardiac symptoms 
according to NCI toxicity score were routinely documented 
during and directly following chemotherapy. Overall, only 
0.3% of patients in the EC-Doc group and 1.1% in the FEC 
group experienced cardiac-associated grade 3 or 4 adverse 
events. Cardiac toxicity could not be evaluated in the long-
term-follow up of ADEBAR patients because no further 
echocardiographic examinations were performed. Regarding 
the cardiotoxicity of anthracyclines, the PACS-01 trial found 
a similar rate of cardiac events at the 5-year follow-up (FEC-
Doc, 0.4%; FEC, 1.3%) [12]. The 10-year follow-up in the 
BCIRG 01 trial found the rate of cardiac problems of grade 
Twice as many patients in the FEC group (8.0%) as in the 
EC-Doc group (3.7%) terminated their therapy (p = 0.002) 
because of toxicity. The rate of denial was identical in both 
groups at 4.4%. There was no significant difference in the 
 frequency of treatment termination due to tumor progression 
between groups (EC-Doc at 0.6%, FEC at 0.5%). 6 deaths 
 occurred during the observation period. In the FEC group, 
1 death was a result of a lung embolism, 1 resulted from per-
forated sigmadiverticulitis during leukopenia, and 2 were due 
to cardiac arrest. In the EC-Doc group, 1 death was caused by 
tumor progression (cerebral metastasis), and 1 by cardiac 
 arrest. On the assessment by the investigators, these deaths 
were not thought to have been a result of the therapy. 
Dose reduction was rarely used during the application of 
EC treatment (0.5%), but was used in 5% of patients during 
the docetaxel treatment cycles, in 3.2% of patients during the 
first cycle of FEC, and in 9.3% during the second cycle of 
FEC therapy. Dose reduction was more often required during 
FEC (12.5%) than during EC-Doc (5.5%) therapy (p = 0.046). 
12% of patients receiving EC-Doc therapy and 17.2% receiv-
ing FEC therapy had extended time intervals between cycles 
(p < 0.001). 
Discussion
Sequential anthracycline-taxane regimens have been reported 
to show good feasibility [11, 12], whereas combined regimens 
have shown higher rates of hematological toxicity [9, 16]. For 
example, in the BCIRG 005 trial, docetaxel in combination 
with doxorubicin and cyclophosphamide (TAC) was associ-
ated with more febrile neutropenia [16]. The PACS 01 trial 
showed that, although patients had improved disease-free sur-
vival and overall survival following sequential taxane therapy 
(using a slightly different chemotherapy regimen than in the 
ADEBAR trial with 3× FEC, followed by 3× Doc), approxi-
mately 11% of them had febrile neutropenia [12]. 
As taxane-containing regimens are effective for nodal-pos-
itive as well as for nodal-negative patients [15, 17, 18], this 
analysis of the toxicities resulting from sequential FEC-Doc 
therapy compared with taxane-free, but dose-dense, FEC120 
therapy from the ADEBAR trial is a novel approach for 
 evaluating the feasibility of these 2 treatment options. The 
treatment arm A (EC-Doc) was chosen in reference to the 
CALBG-9344 and NSABP-B27 trials [19, 20]. The dose of 
docetaxel used was selected for its approximate equivalence 
to the dose of paclitaxel used in the CALBG-9344 trial [19]. 
The treatment arm B (FEC) was chosen in reference to the 
Levine protocol. The Levine regimen has been shown to be 
superior in comparison with CMF therapy in a large random-
ized study [2]. The treatment duration for this regimen was 
identical to that of arm A. The toxicity resulting from applica-
tion of the Levine protocol was high, but was indicative of 
what would have been expected in a dose-intensified anthra-
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Conclusion
The present analysis of the toxicity data from the ADEBAR 
trial has shown that hematological toxicity was a frequent side 
effect of treatment and occurred more often in the FEC120 
treatment arm. Severe non-hematologic toxicities were rare and 
were associated with docetaxel treatment. There were 
 significantly more patients who were removed from therapy 
due to toxicity in the FEC120 arm than in the EC-Doc arm. 
Therefore, we conclude that the sequential anthracycline- 
taxane regimen is a well-tolerated, feasible therapy, which is 
suitable for patients with high-risk, node-positive breast cancer. 
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